白喉毒素突变体CRM197在大肠杆菌中的高效可溶表达、纯化及免疫原性分析

Expression, purification and characterization of diphtheria toxin mutant CRM197 in Eschrichia coli

摘要:

CRM197 (Cross-reacting material 197)是白喉毒素的无毒突变体，在生物制药领域具有非常广泛的应用前景。为了实现CRM197在大肠杆菌中的无标签、可溶表达，以替代现有昂贵、复杂的白喉杆菌分泌发酵工艺，文中对目的蛋白的序列进行优化，转化大肠杆菌经IPTG诱导，目的蛋白获得了可溶性高表达，目的蛋白约占碎菌上清总蛋白的40%。超声破菌后、经阴离子交换、肝素亲和以及脱盐三步柱上层析获得纯度高于95%的CRM197样品。细胞毒性实验证明，CRM197的IC50值是白喉毒素IC50值的 2.1×107倍，是白喉类毒素IC50值的9.6倍，表明文中表达的CRM197是安全无毒的。随后，比较了高、低剂量的CRM197在小鼠体内的免疫原性，发现2 μg组三免后的抗体滴度与20 μg组的相当，可达1︰409 600。文中建立了CRM197的无标签、高效、可溶表达的大肠杆菌表达系和快速纯化体系，获得了具有较好免疫原性和安全性的重组蛋白，为该蛋白的进一步应用奠定了基础。

Abstract:

CRM197 (cross-reacting material 197), a non-toxic mutant of diphtheria toxin, has wide application potential in biopharmaceuticals. However, it is difficult to express CRM197 in bacteria other than Corynebacterium diphtheriae. Here we proposed a new alternative method to produce soluble CRM197 without label in Escherichia coli. In particular, a synthetic gene coding for CRM197, optimized for E. coli codon usage, was cloned in the pET32a (+) vector. Accordingly, the over-expression of the protein was simply induced with IPTG in E. coli BL21 (DE3). The target protein was soluble and accounted for about 40% of the total protein in the supernatant. Following an ultrasonic cytolysis step, the recombinant protein was purified by anion exchange, affinity and desalting chromatography and the purity of the final preparation reached 95%. Cytotoxicity tests showed that the IC50 value of CRM197 was 2.1×107 times the IC50 value of diphtheria toxin, and 9.6 times the IC50?value of diphtheria toxoid, telling that the target protein is safe and non-toxic. Subsequently, we found that both the high dose (20 μg) and the low dose (2 μg) of CRM197 were equally efficient in inducing an immune response against diphtheria?toxiod in mice, and the antibodies titer of mice after three immunizations with low dose could reach 1:409 600. In conclusion, our findings provide a highly efficient strategy for the rapid production and purification of unlabeled and soluble recombinant CRM197 in E. coli, with good immunogenicity and safety.